Michal Kuchar
Psychopharmacology Researcher
Papers
Trials
Key Impact
Notable for contributions to empirical and naturalistic studies of psychedelic compounds—particularly microdosing, psilocybin and 5‑MeO‑DMT—and for work on methodological transparency in psychedelic research.
Background & Research
Michal Kuchar (publishing frequently as M. Kuchar) is a psychopharmacology researcher whose work sits at the intersection of experimental and naturalistic studies of classical and novel psychedelics. He has co‑authored multiple empirical investigations into microdosing effects on cognition and creativity, naturalistic inhalation studies of toad‑derived 5‑MeO‑DMT reporting sustained changes in wellbeing and mindfulness, and studies linking single psilocybin doses to long‑term increases in mindfulness together with proportional changes in neocortical 5‑HT2A receptor binding. Kuchar's collaborations span behavioural, pharmacological and neuroimaging groups, and his papers contribute both primary data and methodological reflection on transparency and reproducibility in the rapidly expanding field of psychedelic science.
Kuchar's contributions emphasise pragmatic, field‑relevant approaches (open‑label and naturalistic designs) alongside more controlled neurobiological investigations, positioning him as a bridge between laboratory neuropharmacology and real‑world psychedelic experiences. He has been involved in multi‑author projects addressing microdosing, the phenomenology of high‑intensity compounds (such as 5‑MeO‑DMT), and the potential utility of psychedelics as tools for modelling altered states of consciousness and therapeutic mechanisms.